When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
VCNX - Vaccinex's pepinemab + avelumab successful in non-small cell lung cancer study; shares up 15% premarket
Vaccinex Inc.
Vaccinex (NASDAQ:VCNX) presents updated interim results from CLASSICAL-Lung, the Phase 1b/2 study of pepinemab in combination with anti-PD-L1 checkpoint inhibitor avelumab (BAVENCIO) in non-small cell lung cancer (NSCLC), at the American Association for Cancer Research.
More news on: Vaccinex, Inc., Healthcare stocks news, Stocks on the move,